Vol 68, No 1 (2010)
Other
Published online: 2010-02-03
Original article
Plasma adiponectin in patients with acute myocardial infarction treated with percutaneous coronary intervention
DOI: 10.33963/v.kp.79971
Kardiol Pol 2010;68(1):11-20.
Abstract
Background: Adiponectin is an adipocytokine with anti-inflammatory and anti-atherogenic properties. It has been also shown to protect cardiomyocytes, suppressing their apoptosis.
Aim: Evaluation of changes in plasma adiponectin concentrations in patients with acute myocardial infarction (AMI) and analysis of their correlations with cardiac ischaemic markers.
Methods: Fifty men with AMI treated with primary coronary angioplasty were included in the study. A control group matched for age and sex consisted of patients without AMI who underwent elective coronary angioplasty. Blood samples were obtained on admission, on the 1st, 3rd and 5th day of AMI, and at follow-up visits after 1 and 3 months.
Results: There were no significant differences in plasma adiponectin concentrations between the groups on admission (4.29 vs. 3.64 mg/ml, p = 0.52). In patients with AMI a significant decrease in plasma adiponectin concentration (to 3.64 mg/ml, p < 0.001) was observed. Plasma adiponectin concentrations at follow-up visits were comparable to those on admission in both groups. Plasma adiponectin concentrations did not correlate with creatine kinase (CK), CK-MB, troponin I, blood glucose or left ventricular ejection fraction.
Conclusions: In patients with AMI plasma adiponectin concentrations significantly decrease, with subsequent increase to initial values after one month. No correlation between plasma adiponectin concentrations and cardiac ischaemic markers or blood glucose was found. The decline in plasma adiponectin concentration may reflect its utilisation in the heart for protection of cardiomyocytes against apoptosis and inflammation.
Aim: Evaluation of changes in plasma adiponectin concentrations in patients with acute myocardial infarction (AMI) and analysis of their correlations with cardiac ischaemic markers.
Methods: Fifty men with AMI treated with primary coronary angioplasty were included in the study. A control group matched for age and sex consisted of patients without AMI who underwent elective coronary angioplasty. Blood samples were obtained on admission, on the 1st, 3rd and 5th day of AMI, and at follow-up visits after 1 and 3 months.
Results: There were no significant differences in plasma adiponectin concentrations between the groups on admission (4.29 vs. 3.64 mg/ml, p = 0.52). In patients with AMI a significant decrease in plasma adiponectin concentration (to 3.64 mg/ml, p < 0.001) was observed. Plasma adiponectin concentrations at follow-up visits were comparable to those on admission in both groups. Plasma adiponectin concentrations did not correlate with creatine kinase (CK), CK-MB, troponin I, blood glucose or left ventricular ejection fraction.
Conclusions: In patients with AMI plasma adiponectin concentrations significantly decrease, with subsequent increase to initial values after one month. No correlation between plasma adiponectin concentrations and cardiac ischaemic markers or blood glucose was found. The decline in plasma adiponectin concentration may reflect its utilisation in the heart for protection of cardiomyocytes against apoptosis and inflammation.
Keywords: adiponectinmyocardial infarctioncoronary artery disease